BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 30092736)

  • 1. Clinical subsets of juvenile dermatomyositis classified by myositis-specific autoantibodies: Experience at a single center in Japan.
    Iwata N; Nakaseko H; Kohagura T; Yasuoka R; Abe N; Kawabe S; Sugiura S; Muro Y
    Mod Rheumatol; 2019 Sep; 29(5):802-807. PubMed ID: 30092736
    [No Abstract]   [Full Text] [Related]  

  • 2. [Dermatomyositis and Autoantibodies].
    Fujimoto M
    Brain Nerve; 2018 Apr; 70(4):427-438. PubMed ID: 29632290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent research on myositis-specific autoantibodies in juvenile dermatomyositis.
    He L
    Zhongguo Dang Dai Er Ke Za Zhi; 2021 Oct; 23(10):1064-1068. PubMed ID: 34719424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
    Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
    Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Four dermatomyositis-specific autoantibodies-anti-TIF1γ, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort.
    Bodoki L; Nagy-Vincze M; Griger Z; Betteridge Z; Szöllősi L; Dankó K
    Autoimmun Rev; 2014 Dec; 13(12):1211-9. PubMed ID: 25182203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy.
    Ichimura Y; Matsushita T; Hamaguchi Y; Kaji K; Hasegawa M; Tanino Y; Inokoshi Y; Kawai K; Kanekura T; Habuchi M; Igarashi A; Sogame R; Hashimoto T; Koga T; Nishino A; Ishiguro N; Sugimoto N; Aoki R; Ando N; Abe T; Kanda T; Kuwana M; Takehara K; Fujimoto M
    Ann Rheum Dis; 2012 May; 71(5):710-3. PubMed ID: 22258483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MDA5 autoantibodies associated with juvenile dermatomyositis constitute a distinct phenotype in North America.
    Mamyrova G; Kishi T; Shi M; Targoff IN; Huber AM; Curiel RV; Miller FW; Rider LG;
    Rheumatology (Oxford); 2021 Apr; 60(4):1839-1849. PubMed ID: 33140079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The analysis of clinical phenotypes and autoantibodies in juvenile dermatomyositis].
    Li DM; Wang L; Liu MY; Xu L; Tang XM
    Zhonghua Er Ke Za Zhi; 2020 Dec; 58(12):966-972. PubMed ID: 33256317
    [No Abstract]   [Full Text] [Related]  

  • 10. Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis.
    Aouizerate J; De Antonio M; Bader-Meunier B; Barnerias C; Bodemer C; Isapof A; Quartier P; Melki I; Charuel JL; Bassez G; Desguerre I; Gherardi RK; Authier FJ; Gitiaux C
    Rheumatology (Oxford); 2018 May; 57(5):873-879. PubMed ID: 29474663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent advances in dermatomyositis-specific autoantibodies.
    Fujimoto M; Watanabe R; Ishitsuka Y; Okiyama N
    Curr Opin Rheumatol; 2016 Nov; 28(6):636-44. PubMed ID: 27533321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study.
    Yamasaki Y; Kobayashi N; Akioka S; Yamazaki K; Takezaki S; Nakaseko H; Ohara A; Nishimura K; Nishida Y; Sato S; Kishi T; Hashimoto M; Mori M; Okazaki Y; Kuwana M; Ohta A
    Rheumatology (Oxford); 2021 Oct; 60(10):4821-4831. PubMed ID: 33576399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dermatomyositis: new antibody, new classification].
    Bolko L; Gitiaux C; Allenbach Y
    Med Sci (Paris); 2019 Nov; 35 Hors série n° 2():18-23. PubMed ID: 31859626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients.
    Betteridge Z; Tansley S; Shaddick G; Chinoy H; Cooper RG; New RP; Lilleker JB; Vencovsky J; Chazarain L; Danko K; Nagy-Vincze M; Bodoki L; Dastmalchi M; Ekholm L; Lundberg IE; McHugh N;
    J Autoimmun; 2019 Jul; 101():48-55. PubMed ID: 30992170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Calcinosis in juvenile dermatomyositis is influenced by both anti-NXP2 autoantibody status and age at disease onset.
    Tansley SL; Betteridge ZE; Shaddick G; Gunawardena H; Arnold K; Wedderburn LR; McHugh NJ;
    Rheumatology (Oxford); 2014 Dec; 53(12):2204-8. PubMed ID: 24987158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In-depth proteomic analysis of juvenile dermatomyositis serum reveals protein expression associated with muscle-specific autoantibodies.
    Sato H; Inoue Y; Kawashima Y; Konno R; Ohara O; Kuwana M; Kobayashi N; Takezaki S; Akioka S
    Rheumatology (Oxford); 2023 Oct; 62(10):3501-3506. PubMed ID: 37052527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastrointestinal perforation in anti-NXP2 antibody-associated juvenile dermatomyositis: case reports and a review of the literature.
    Xu Y; Ma X; Zhou Z; Li J; Hou J; Zhu J; Kang M; Lai J; Li X
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):2. PubMed ID: 33407602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
    Hoshino K; Muro Y; Sugiura K; Tomita Y; Nakashima R; Mimori T
    Rheumatology (Oxford); 2010 Sep; 49(9):1726-33. PubMed ID: 20501546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and poor predictors of anti-NXP2 antibody-associated Chinese JDM children.
    Wang X; Ding Y; Zhou Z; Hou J; Xu Y; Li J
    Pediatr Rheumatol Online J; 2021 Jan; 19(1):6. PubMed ID: 33407621
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.